Drug
Mivelsiran
Mivelsiran: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mivelsiran NCT07636811 | Phase 2 | Down Syndrome-Associated Alzheimer's Disease (DS-AD) |
Latest
No recent events.
Follow Mivelsiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.